Larry W Kwak

List of Publications by Year
in descending order

204	13,527	22153	23533
papers	citations	59 h-index	111 g-index

207	207	207	14663
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 89-97.	0.4	6
2	A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. Blood, 2022, 139, 1289-1301.	1.4	9
3	CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia. Leukemia, 2022, 36, 1015-1024.	7.2	15
4	Immortalized B Cells Transfected With mRNA of Antigen Fused to MITD (IBMAM): An Effective Immunological Tool for In-Vitro Immune-Monitoring of Antigen-specific T Cells. JCO Global Oncology, 2022, 8, 21-21.	1.8	0
5	The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. Cancer Immunology Research, 2021, 9, 75-88.	3.4	24
6	Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP. Clinical Cancer Research, 2021, 27, 1671-1680.	7.0	24
7	Targeted InÂVivo Delivery of NF-ÎºB Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy. Molecular Therapy, 2021, 29, 1214-1225.	8.2	6
8	Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. Blood Advances, 2021, 5, 3354-3361.	5.2	6
9	Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions. Cancer Immunology, Immunotherapy, 2020, 69, 2139-2145.	4.2	14
10	Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. Clinical Cancer Research, 2020, 26, 1034-1044.	7.0	48
11	The changing investment in translational science by academic medical centers: HOPE in the Valley of Death. Journal of Clinical Investigation, 2020, 130, 3333-3335.	8.2	5
12	Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma. Blood, 2020, 136, 27-28.	1.4	1
13	A Novel Therapeutic DNA Vaccine Elicits Reduction of Tumor Clones and Favorable Perturbations in the Immune Microenvironment in Patients (pts) with Untreated Smoldering WaldenstrÃ¶m Macroglobulinemia (sWM). Blood, 2020, 136, 6-7.	1.4	0
14	CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Science Translational Medicine, 2019, 11, .	12.4	67
15	Longâ€term overallâ€•and progressionâ€free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent nonâ€Hodgkin lymphoma. British Journal of Haematology, 2019, 185, 670-678.	2.5	7
16	Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. Blood, 2019, 133, 306-318.	1.4	26
17	B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. Molecular Therapy, 2018, 26, 695-707.	8.2	25
18	Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer, 2018, 124, 2561-2569.	4.1	14

#	Article	IF	Citations
19	Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies In Vivo. Clinical Cancer Research, 2018, 24, 1114-1123.	7.0	25
20	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 514-520.	2.0	31
21	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. Lancet Haematology,the, 2018, 5, e543-e553.	4.6	53
22	Targeting myeloid-derived suppressor cells for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2018, 67, 1181-1195.	4.2	95
23	Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. Journal of Hematology and Oncology, 2018, 11, 87.	17.0	12
24	Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer, 2018, 18, 187.	2.6	16
25	Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma. Blood, 2018, 132, 1636-1636.	1.4	5
26	Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors. Blood, 2018, 132, 1411-1411.	1.4	0
27	Absence of Grail promotes CD8+ T cell anti-tumour activity. Nature Communications, 2017, 8, 239.	12.8	22
28	CTLA4 Promotes Tyk2-STAT3â€“Dependent B-cell Oncogenicity. Cancer Research, 2017, 77, 5118-5128.	0.9	34
29	Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Biology of Blood and Marrow Transplantation, 2017, 23, 1861-1869.	2.0	19
30	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematology,the, 2017, 4, e362-e373.	4.6	70
31	Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Research, 2017, 27, 1034-1045.	12.0	259
32	Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 24-31.	1.6	152
33	Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma. Blood, 2017, 130, 738-738.	1.4	5
34	Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma.. Journal of Clinical Oncology, 2017, 35, 7532-7532.	1.6	2
35	Overview of lymphoma. , 2017, , 1-9.		0
36	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17

#	Article	IF	Citations
37	CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. Immunity, 2016, 44, 913-923.	14.3	120
38	IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay. OncoImmunology, 2016, 5, e1237327.	4.6	17
39	Rituximab plus hyperâ€‹<scp>CVAD</scp> alternating with <scp>MTX</scp>/Araâ€€ in patients with newly diagnosed mantle cell lymphoma: 15â€‹year followâ€‹up of a phase <scp>II</scp> study from the <scp>MD</scp> Anderson Cancer Center. British Journal of Haematology, 2016, 172, 80-88.	2.5	82
40	Targeting B-cell malignancies through human B-cell receptor specific CD4+T cells. OncoImmunology, 2016, 5, e1232220.	4.6	5
41	Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial. Leukemia and Lymphoma, 2016, 57, 445-447.	1.3	5
42	Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL). Blood, 2016, 128, 1807-1807.	1.4	11
43	Quantitative Baseline Circulating Tumor DNA Levels Correlate with GM-CSF Response to Idiotype Vaccine in Untreated Mantle Cell Lymphoma. Blood, 2016, 128, 2943-2943.	1.4	0
44	Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica, 2015, 100, e272-e274.	3.5	17
45	CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology, 2015, 171, 726-735.	2.5	50
46	Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. British Journal of Haematology, 2015, 171, 463-470.	2.5	81
47	Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, lowâ€grade Bâ€cell lymphomas. British Journal of Haematology, 2015, 169, 814-823.	2.5	5
48	Phase <scp>II</scp> study of <scp>HCVIDD</scp>/<scp>MA</scp> in patients with newly diagnosed peripheral Tâ€cell lymphoma. British Journal of Haematology, 2015, 171, 509-516.	2.5	15
49	Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a nextâ€generation sequencing approach. British Journal of Haematology, 2015, 169, 689-693.	2.5	36
50	Targeting tumor-associated myeloid cells for cancer immunotherapy. OncoImmunology, 2015, 4, e983961.	4.6	9
51	Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 152-158.	0.4	34
52	Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. Blood, 2015, 126, 519-519.	1.4	9
53	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. Blood, 2015, 126, 522-522.	1.4	3
54	Anti-Î²2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. Oncotarget, 2015, 6, 8567-8578.	1.8	26

#	Article	IF	Citations
55	Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget, 2015, 6, 34329-34341.	1.8	123
56	Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation. Blood, 2015, 126, 1961-1961.	1.4	0
57	Induction of p53â€mediated transcription and apoptosis by exportinâ€1 (<scp>XPO</scp>1) inhibition in mantle cell lymphoma. Cancer Science, 2014, 105, 795-801.	3.9	81
58	⁹⁰Yâ€ibritumomab tiuxetan radiotherapy as firstâ€line therapy for early stage lowâ€grade Bâ€cell lymphomas, including bulky disease. British Journal of Haematology, 2014, 167, 207-213.	2.5	27
59	Rush Hour Traffic: Directing T Cells to Tumor. Journal of the National Cancer Institute, 2014, 106, dju301-dju301.	6.3	0
60	Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncology, The, 2014, 15, 69-77.	10.7	518
61	The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. British Journal of Haematology, 2014, 165, 112-116.	2.5	50
62	Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood, 2014, 123, 2204-2208.	1.4	66
63	Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nature Medicine, 2014, 20, 676-681.	30.7	199
64	Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncology, The, 2014, 15, 1311-1318.	10.7	239
65	Double hit lymphoma: the <scp>MD A</scp>nderson <scp>C</scp>ancer <scp>C</scp>enter clinical experience. British Journal of Haematology, 2014, 166, 891-901.	2.5	310
66	Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. International Journal of Cancer, 2014, 135, 2834-2846.	5.1	31
67	The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. Biomaterials, 2014, 35, 5491-5504.	11.4	108
68	Cloning Variable Region Genes of Clonal Lymphoma Immunoglobulin for Generating Patient-Specific Idiotype DNA Vaccine. Methods in Molecular Biology, 2014, 1139, 289-303.	0.9	3
69	Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes. American Journal of Blood Research, 2014, 4, 46-52.	0.6	4
70	Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 99-105.	0.4	25
71	Prospective phase <scp>II</scp> study of rituximab with alternating cycles of hyperâ€<scp>CVAD</scp> and highâ€dose methotrexate with cytarabine for young patients with highâ€risk diffuse large <scp>B</scp>â€cell lymphoma. British Journal of Haematology, 2013, 163, 611-620.	2.5	23
72	The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 15-18.	0.4	32

#	Article	IF	Citations
73	Antibodies Targeting Human OX40 Expand Effector T Cells and Block Inducible and Natural Regulatory T Cell Function. Journal of Immunology, 2013, 191, 3641-3650.	0.8	86
74	Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica, 2013, 98, 1458-1466.	3.5	58
75	In Vitro and In Vivo Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome. Molecular Cancer Therapeutics, 2013, 12, 2494-2504.	4.1	22
76	Phase I study of vorinostat in combination with standard <scp>CHOP</scp> in patients with newly diagnosed peripheral Tâ€cell lymphoma. British Journal of Haematology, 2013, 162, 138-141.	2.5	37
77	Nonstereotyped Lymphoma B Cell Receptors Recognize Vimentin as a Shared Autoantigen. Journal of Immunology, 2013, 190, 4887-4898.	0.8	45
78	Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma. Clinical Cancer Research, 2013, 19, 6882-6890.	7.0	103
79	Nuclear Translocation of B-Cell-Specific Transcription Factor, BACH2, Modulates ROS Mediated Cytotoxic Responses in Mantle Cell Lymphoma. PLoS ONE, 2013, 8, e69126.	2.5	30
80	Bone Marrow Stromal Cells Derived MCP-1 Reverses the Inhibitory Effects of Multiple Myeloma Cells on Osteoclastogenesis by Upregulating the RANK Expression. PLoS ONE, 2013, 8, e82453.	2.5	8
81	Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes. Journal of Clinical Oncology, 2012, 30, 4161-4167.	1.6	137
82	T cells and T cell tumors efficiently generate antigen-specific cytotoxic T cell immunity when modified with an NKT ligand. OncoImmunology, 2012, 1, 141-151.	4.6	2
83	p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction. Cancer Research, 2012, 72, 6393-6402.	0.9	66
84	Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities. Blood, 2012, 119, 2568-2578.	1.4	21
85	Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood, 2012, 119, 161-169.	1.4	103
86	Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood, 2012, 120, 3783-3792.	1.4	100
87	Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production. British Journal of Haematology, 2012, 159, 243-246.	2.5	8
88	Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncology, The, 2012, 13, 716-723.	10.7	274
89	Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leukemia and Lymphoma, 2012, 53, 50-56.	1.3	26
90	Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. Journal of Clinical Oncology, 2012, 30, 2776-2782.	1.6	162

#	Article	IF	Citations
91	Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood, 2012, 119, 4123-4128.	1.4	70
92	TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood, 2012, 120, 1613-1623.	1.4	33
93	MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. Haematologica, 2012, 97, 586-594.	3.5	110
94	Temporal and geographic variations of Waldenstrom macroglobulinemia incidence. Cancer, 2012, 118, 3793-3800.	4.1	104
95	Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. Journal of Molecular Medicine, 2012, 90, 695-706.	3.9	50
96	Bortezomib-resistant nuclear factor Î¹B expression in stem-like cells in mantle cell lymphoma. Experimental Hematology, 2012, 40, 107-118.e2.	0.4	17
97	Lymphoma Vaccine Therapy: Next Steps After a Positive, Controlled Phase III Clinical Trial. Seminars in Oncology, 2012, 39, 253-262.	2.2	9
98	Translational development of vaccination strategies in follicular NHL. Best Practice and Research in Clinical Haematology, 2011, 24, 295-304.	1.7	7
99	Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. British Journal of Haematology, 2011, 154, 284-286.	2.5	23
100	Targeting cell surface Î²₂â€microglobulin by pentameric IgM antibodies. British Journal of Haematology, 2011, 154, 111-121.	2.5	11
101	An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. Journal of Controlled Release, 2011, 155, 184-192.	9.9	72
102	Cancer Vaccines: Moving toward Prevention?. Cancer Prevention Research, 2011, 4, 954-956.	1.5	2
103	Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma. Journal of Clinical Oncology, 2011, 29, 2787-2794.	1.6	230
104	Idiotype Vaccination As Consolidation Therapy: Time for Integration Into Standard of Care for Follicular Lymphoma?. Journal of Clinical Oncology, 2011, 29, 4845-4846.	1.6	11
105	Targeting Human B-cell Malignancies through Ig Light Chainâ€“Specific Cytotoxic T Lymphocytes. Clinical Cancer Research, 2011, 17, 5945-5952.	7.0	9
106	Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Research, 2010, 5, 212-225.	0.7	26
107	Tenâ€year followâ€up after intense chemoimmunotherapy with RituximabâHyperCVAD alternating with RituximabâHigh dose methotrexate/cytarabine (Râ€MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. British Journal of Haematology, 2010, 150, 200-208.	2.5	213
108	Phase I trial of bortezomib in combination with rituximabâHyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. British Journal of Haematology, 2010, 151, 47-53.	2.5	49

#	Article	IF	Citations
109	Prime-Boost Vaccination Using Chemokine-Fused gp120 DNA and HIV Envelope Peptides Activates Both Immediate and Long-Term Memory Cellular Responses in Rhesus Macaques. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7.	3.0	6
110	Identification of Human Idiotype-Specific T Cells in Lymphoma and Myeloma. Current Topics in Microbiology and Immunology, 2010, 344, 193-210.	1.1	12
111	Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2445-2452.	2.5	45
112	Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines. Vaccine, 2010, 28, 7970-7978.	3.8	5
113	Human-Like Mouse Models for Testing the Efficacy and Safety of Anti-Î²2-Microglobulin Monoclonal Antibodies to Treat Myeloma. Clinical Cancer Research, 2009, 15, 951-959.	7.0	19
114	Myeloma cell lineâ€“derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood, 2009, 114, 3880-3889.	1.4	31
115	IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood, 2009, 114, 360-370.	1.4	50
116	Cancer vaccines: up, down, â€¦ up again?. Blood, 2009, 113, 1-2.	1.4	107
117	Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cellâ€“, and not B cellâ€“, dependent antilymphoma immunity. Blood, 2009, 114, 4142-4149.	1.4	32
118	Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer, 2008, 113, 791-798.	4.1	219
119	Phase 2 trial of rituximab plus hyperâ€CVAD alternating with rituximab plus methotrexateâ€cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer, 2008, 113, 2734-2741.	4.1	31
120	Immunotherapy in mantle cell lymphoma: Anti-CD20-based therapy and beyond. American Journal of Hematology, 2008, 83, 144-149.	4.1	19
121	Phase II multicenter study of oblimersen sodium, a Bclâ€2 antisense oligonucleotide, in combination with rituximab in patients with recurrent Bâ€cell nonâ€Hodgkin lymphoma. British Journal of Haematology, 2008, 143, 355-360.	2.5	93
122	A novel strategy for rapid and efficient isolation of human tumor-specific CD4+ and CD8+ T-cell clones. Journal of Immunological Methods, 2008, 331, 13-26.	1.4	15
123	Roles of Idiotype-Specific T Cells in Myeloma Cell Growth and Survival: Th1 and CTL Cells Are Tumoricidal while Th2 Cells Promote Tumor Growth. Cancer Research, 2008, 68, 8456-8464.	0.9	61
124	A Severe Combined Immunodeficientâ€“hu In vivo Mouse Model of Human Primary Mantle Cell Lymphoma. Clinical Cancer Research, 2008, 14, 2154-2160.	7.0	26
125	Efficient Modulation of T-cell Response by Dual-mode, Single-carrier Delivery of Cytokine-targeted siRNA and DNA Vaccine to Antigen-presenting Cells. Molecular Therapy, 2008, 16, 2011-2021.	8.2	61
126	Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood, 2008, 111, 5530-5536.	1.4	294

#	Article	IF	Citations
127	Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma. Blood, 2008, 112, 3051-3051.	1.4	5
128	Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies. Hematology American Society of Hematology Education Program, 2007, 2007, 243-249.	2.5	9
129	Prognostic significance of serum B-lymphocyte stimulator level in Hodgkin's lymphoma. Haematologica, 2007, 92, 269-270.	3.5	16
130	A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. Blood, 2007, 109, 5407-5410.	1.4	18
131	An NKT-mediated autologous vaccine generates CD4 T-cellâ€“dependent potent antilymphoma immunity. Blood, 2007, 110, 2013-2019.	1.4	66
132	A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood, 2007, 109, 5160-5163.	1.4	33
133	Antiâ€“Î²2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood, 2007, 110, 3028-3035.	1.4	52
134	Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine, 2007, 25, 7955-7961.	3.8	42
135	Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood, 2007, 110, 1587-1594.	1.4	115
136	Elevated serum BLyS levels in patients with non-Hodgkin lymphoma. Leukemia and Lymphoma, 2007, 48, 1869-1871.	1.3	11
137	Therapeutic Vaccine for Lymphoma. Yonsei Medical Journal, 2007, 48, 1.	2.2	7
138	Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer, 2007, 109, 77-83.	4.1	48
139	Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer, 2007, 109, 2481-2489.	4.1	138
140	Human C-Reactive Protein Binds Activating FcÎ³ Receptors and Protects Myeloma Tumor Cells from Apoptosis. Cancer Cell, 2007, 12, 252-265.	16.8	112
141	Molecular analysis of light-chain switch and acute lymphoblastic leukemia transformation in two follicular lymphomas: Implications for lymphomagenesis. Leukemia and Lymphoma, 2006, 47, 1523-1534.	1.3	32
142	Therapeutic lymphoma vaccines: importance of T-cell immunity. Expert Review of Vaccines, 2006, 5, 381-394.	4.4	18
143	Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood, 2006, 107, 2432-2439.	1.4	97
144	Myeloma wrecks Treg?. Blood, 2006, 107, 8-9.	1.4	0

#	Article	IF	Citations
145	Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood, 2006, 108, 4071-4077.	1.4	87
146	Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood, 2006, 108, 2407-2415.	1.4	71
147	Targeting Î²2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell, 2006, 10, 295-307.	16.8	92
148	Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. Journal of Controlled Release, 2006, 113, 261-270.	9.9	81
149	Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera. Journal of Immunological Methods, 2006, 312, 79-93.	1.4	4
150	Doseâ€Related Safety and Immunogenicity of Baculovirusâ€Expressed Trivalent Influenza Vaccine: A Doubleâ€Blind, Controlled Trial in Adult Patients with Nonâ€Hodgkin B Cell Lymphoma. Journal of Infectious Diseases, 2006, 194, 1394-1397.	4.0	42
151	623. Polymer Microparticles Delivering a Idiotype/Chemokine Fusion DNA Vaccine Generate Protective Immunity in a Mice Model of B Cell Lymphoma. Molecular Therapy, 2006, 13, S240.	8.2	0
152	Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups.. Blood, 2006, 108, 2742-2742.	1.4	9
153	Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nature Medicine, 2005, 11, 986-991.	30.7	106
154	Phase III Randomized Trial of Patient-Specific Vaccination for Previously Untreated Patients with Follicular Lymphoma in First Complete Remission: Protocol Summary and Interim Report. Clinical Lymphoma and Myeloma, 2005, 6, 61-64.	2.1	26
155	B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood, 2005, 106, 795-802.	1.4	114
156	Therapeutic idiotype vaccines in B lymphoproliferative diseases. Expert Opinion on Biological Therapy, 2004, 4, 959-963.	3.1	11
157	Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen. Clinical Cancer Research, 2004, 10, 8309-8317.	7.0	75
158	Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies. Clinical Cancer Research, 2004, 10, 1047-1056.	7.0	19
159	Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. Journal of Leukocyte Biology, 2004, 76, 77-85.	3.3	28
160	Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Laboratory Investigation, 2004, 84, 235-244.	3.7	84
161	Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. Seminars in Oncology, 2004, 31, 37-46.	2.2	18
162	Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry. Proteomics, 2004, 4, 1195-1203.	2.2	137

#	Article	IF	Citations
163	A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. Journal of Translational Medicine, 2004, 2, 9.	4.4	36
164	Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood, 2004, 104, 1961-1969.	1.4	55
165	Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. Journal of Clinical Investigation, 2004, 113, 1498-1510.	8.2	57
166	Human Autologous Tumor-Specific T-Cell Responses Induced by Liposome Encapsulated Lymphoma Membrane Proteins.. Blood, 2004, 104, 749-749.	1.4	3
167	Vaccination strategies for lymphomas. Current Oncology Reports, 2003, 5, 380-386.	4.0	5
168	Translational development of active immunotherapy for hematologic malignancies. Seminars in Oncology, 2003, 30, 17-22.	2.2	16
169	In vitroPriming of Myeloma Antigen-specific Allogeneic Donor T Cells with Idiotype Pulsed Dendritic Cells. Leukemia and Lymphoma, 2003, 44, 1201-1208.	1.3	14
170	DNA vaccines encoding human immunodeficiency virusâ€“1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood, 2002, 100, 1153-1159.	1.4	127
171	Current Status of Recombinant Idiotype Vaccines for the Treatment of Follicular Non-Hodgkin's Lymphoma. Clinical Lymphoma and Myeloma, 2002, 3, 147-149.	2.1	0
172	Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by Î²-Defensin 2. Science, 2002, 298, 1025-1029.	12.6	870
173	Mammalian defensins in immunity: more than just microbicidal. Trends in Immunology, 2002, 23, 291-296.	6.8	647
174	Translational development of active immunotherapy for hematologic malignancies. International Journal of Hematology, 2002, 76, 320-321.	1.6	0
175	Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica, 2002, 87, 989-1001.	3.5	51
176	Models for Lymphoma. Current Protocols in Immunology, 2001, 46, Unit 20.6.	3.6	1
177	Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine. Journal of Cancer Research and Clinical Oncology, 2001, 127, R14-R19.	2.5	12
178	Immunotherapy of multiple myeloma. Seminars in Hematology, 2001, 38, 260-267.	3.4	23
179	Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines. Journal of Clinical Oncology, 2001, 19, 1848-1854.	1.6	113
180	Novel Secondary Ig VHGene Rearrangement and In-Frame Ig Heavy Chain Complementarity-Determining Region III Insertion/Deletion Variants in De Novo Follicular Lymphoma. Journal of Immunology, 2001, 166, 2235-2243.	0.8	19

#	Article	IF	Citations
181	Mediators of Innate Immunity That Target Immature, But Not Mature, Dendritic Cells Induce Antitumor Immunity When Genetically Fused with Nonimmunogenic Tumor Antigens. Journal of Immunology, 2001, 167, 6644-6653.	0.8	284
182	Designer cancer vaccines are still in fashion. Nature Medicine, 2000, 6, 966-968.	30.7	23
183	Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. Blood, 2000, 96, 2828-2833.	1.4	106
184	Approaches for Immunotherapy of Lymphomas. Immunological Investigations, 2000, 29, 93-95.	2.0	1
185	Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. International Immunology, 2000, 12, 691-700.	4.0	182
186	Serum BCL2/IGH DNA in Follicular Lymphoma Patients: A Minimal Residual Disease Marker. Leukemia and Lymphoma, 2000, 39, 165-172.	1.3	8
187	Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. Blood, 2000, 96, 2828-2833.	1.4	7
188	Complete molecular remissions induced by patient-specific vaccination plus granulocyteâ€“monocyte colony-stimulating factor against lymphoma. Nature Medicine, 1999, 5, 1171-1177.	30.7	573
189	B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions. Immunological Reviews, 1999, 170, 115-126.	6.0	26
190	Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nature Biotechnology, 1999, 17, 253-258.	17.5	278
191	Mechanisms of resistance against B-cell malignancies induced by vaccination against the immunoglobulin receptor: the case for T-cell immunity. , 1999, 99, 267-273.		1
192	Development of Vaccine Strategies for the Treatment of B-Cell Malignancies. Cancer Investigation, 1997, 15, 577-587.	1.3	20
193	Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma â€" Long-Term Results of a Clinical Trial. Blood, 1997, 89, 3129-3135.	1.4	461
194	The current status of human cancer vaccines. Expert Opinion on Investigational Drugs, 1994, 3, 1241-1253.	4.1	3
195	Immunoglobulin idiotype antigen vaccines for the treatment of lymphomas. Clinical Immunology Newsletter, 1994, 14, 121-124.	0.1	0
196	MACOP-B Â± radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford Results According to Prognostic Indices. Cancer, 1993, 71, 4034-4042.	4.1	9
197	Cytotoxic T-Cell Response and In Vivo Protection Against Tumor Cells Harboring Activated ras Proto-oncogenes. Journal of the National Cancer Institute, 1993, 85, 1294-1302.	6.3	64
198	Induction of Immune Responses in Patients with B-Cell Lymphoma against the Surface-Immunoglobulin Idiotype Expressed by Their Tumors. New England Journal of Medicine, 1992, 327, 1209-1215.	27.0	542

#	Article	IF	Citations
199	Clinical significance of morphologic subdivision in diffuse large cell lymphoma. Cancer, 1991, 68, 1988-1993.	4.1	48
200	The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: Preliminary data. Annals of Oncology, 1991, 2, 47-50.	1.2	52
201	Follicular lymphoma: A model of lymphoid tumor progression in man. Annals of Oncology, 1991, 2, 115-122.	1.2	24
202	GENETICS AND IMMUNOLOGY OF THE P815-X2 MODEL11Supported by NIH Grants CA19791, CA27599, and CA27955. , 1985, , 363-367.		0
203	Immune response to the H-X antigen on P815-X2. Immunogenetics, 1984, 20, 481-491.	2.4	0
204	Evidence for involvement of the H-2K b and I-A b genes in hybrid resistance to P815-X2. Immunogenetics, 1981, 13, 351-353.	2.4	5